GNA Biosolutions Reveals New Ultrafast PCR Platform at Medical Trade Show
By LabMedica International staff writers Posted on 15 Nov 2017 |
Image: The Pharos V8 laser PCR platform (Photo courtesy of GNA Biosolutions).
GNA Biosolutions GmbH (Martinsried, Germany), a molecular technology company, will showcase its new Pharos V8, the world's first laser PCR platform, at MEDICA 2017.
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance